Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways

James B. Macdonald, Brooke Macdonald, Loren E. Golitz, Patricia LoRusso, Aleksandar D Sekulic

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The last decade has spawned an exciting new era of oncotherapy in dermatology, including the development of targeted therapies for metastatic melanoma and basal cell carcinoma. Along with skin cancer, deregulation of the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK intracellular signaling pathways contributes to tumorigenesis of a multitude of other cancers, and inhibitors of these pathways are being actively studied. Similar to other classes of targeted therapies, cutaneous adverse effects are among the most frequent toxicities observed with mitogen-activated protein kinase pathway inhibitors, PI3K-AKTmTOR inhibitors, hedgehog signaling pathway inhibitors, and immunotherapies. Given the rapid expansion of these families of targeted treatments, dermatologists will be essential in offering dermatologic supportive care measures to cancer patients being treated with these agents. Part II of this continuing medical education article reviews skin-related adverse sequelae, including the frequency of occurrence and the implications associated with on- and off-target cutaneous toxicities of inhibitors of the RAS-RAF-MEKERK pathway, PI3K-AKT-mTOR pathway, hedgehog signaling pathway, and immunotherapies.

Original languageEnglish (US)
Pages (from-to)221-236
Number of pages16
JournalJournal of the American Academy of Dermatology
Volume72
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Phosphatidylinositol 3-Kinases
Immunotherapy
Skin
Continuing Medical Education
Basal Cell Carcinoma
Mitogen-Activated Protein Kinase Kinases
Skin Neoplasms
Protein Kinase Inhibitors
Dermatology
Mitogen-Activated Protein Kinases
Melanoma
Neoplasms
Carcinogenesis
Therapeutics

Keywords

  • AKT inhibitor
  • Autoimmune adverse effects
  • Autoimmune dermopathies
  • B-RAF
  • Dabrafenib
  • Dermatitis
  • Dual inhibitor
  • Dysgeusia
  • Everolimus
  • Hair loss
  • Hedgehog signaling pathway
  • Immune-related toxicities
  • Immunotherapy
  • Ipilimumab
  • Keratoacanthoma
  • Keratosis pilaris
  • Keratotic squamoproliferative lesion
  • Lambrolizumab
  • Loss of taste
  • MAP kinase pathway
  • MEK inhibitors
  • mTOR inhibitor
  • Nivolumab
  • Panniculitis
  • PD-1 inhibitor
  • PI3 kinase inhibitor
  • PI3K-AKT-mTOR pathway
  • Pruritus
  • RAF inhibitors
  • Rapamycin
  • RAS
  • Seborrheic dermatitis
  • Selumetinib
  • Squamous cell carcinoma
  • Taste alteration
  • Temsirolimus
  • Trametinib
  • Vemurafenib
  • Verrucal keratosis
  • Vismodegib
  • Vitiligo

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Cutaneous adverse effects of targeted therapies : Part II: Inhibitors of intracellular molecular signaling pathways. / Macdonald, James B.; Macdonald, Brooke; Golitz, Loren E.; LoRusso, Patricia; Sekulic, Aleksandar D.

In: Journal of the American Academy of Dermatology, Vol. 72, No. 2, 2015, p. 221-236.

Research output: Contribution to journalArticle

Macdonald, James B. ; Macdonald, Brooke ; Golitz, Loren E. ; LoRusso, Patricia ; Sekulic, Aleksandar D. / Cutaneous adverse effects of targeted therapies : Part II: Inhibitors of intracellular molecular signaling pathways. In: Journal of the American Academy of Dermatology. 2015 ; Vol. 72, No. 2. pp. 221-236.
@article{9649841a874f4888a237c2a0e4087c57,
title = "Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways",
abstract = "The last decade has spawned an exciting new era of oncotherapy in dermatology, including the development of targeted therapies for metastatic melanoma and basal cell carcinoma. Along with skin cancer, deregulation of the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK intracellular signaling pathways contributes to tumorigenesis of a multitude of other cancers, and inhibitors of these pathways are being actively studied. Similar to other classes of targeted therapies, cutaneous adverse effects are among the most frequent toxicities observed with mitogen-activated protein kinase pathway inhibitors, PI3K-AKTmTOR inhibitors, hedgehog signaling pathway inhibitors, and immunotherapies. Given the rapid expansion of these families of targeted treatments, dermatologists will be essential in offering dermatologic supportive care measures to cancer patients being treated with these agents. Part II of this continuing medical education article reviews skin-related adverse sequelae, including the frequency of occurrence and the implications associated with on- and off-target cutaneous toxicities of inhibitors of the RAS-RAF-MEKERK pathway, PI3K-AKT-mTOR pathway, hedgehog signaling pathway, and immunotherapies.",
keywords = "AKT inhibitor, Autoimmune adverse effects, Autoimmune dermopathies, B-RAF, Dabrafenib, Dermatitis, Dual inhibitor, Dysgeusia, Everolimus, Hair loss, Hedgehog signaling pathway, Immune-related toxicities, Immunotherapy, Ipilimumab, Keratoacanthoma, Keratosis pilaris, Keratotic squamoproliferative lesion, Lambrolizumab, Loss of taste, MAP kinase pathway, MEK inhibitors, mTOR inhibitor, Nivolumab, Panniculitis, PD-1 inhibitor, PI3 kinase inhibitor, PI3K-AKT-mTOR pathway, Pruritus, RAF inhibitors, Rapamycin, RAS, Seborrheic dermatitis, Selumetinib, Squamous cell carcinoma, Taste alteration, Temsirolimus, Trametinib, Vemurafenib, Verrucal keratosis, Vismodegib, Vitiligo",
author = "Macdonald, {James B.} and Brooke Macdonald and Golitz, {Loren E.} and Patricia LoRusso and Sekulic, {Aleksandar D}",
year = "2015",
doi = "10.1016/j.jaad.2014.07.033",
language = "English (US)",
volume = "72",
pages = "221--236",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Cutaneous adverse effects of targeted therapies

T2 - Part II: Inhibitors of intracellular molecular signaling pathways

AU - Macdonald, James B.

AU - Macdonald, Brooke

AU - Golitz, Loren E.

AU - LoRusso, Patricia

AU - Sekulic, Aleksandar D

PY - 2015

Y1 - 2015

N2 - The last decade has spawned an exciting new era of oncotherapy in dermatology, including the development of targeted therapies for metastatic melanoma and basal cell carcinoma. Along with skin cancer, deregulation of the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK intracellular signaling pathways contributes to tumorigenesis of a multitude of other cancers, and inhibitors of these pathways are being actively studied. Similar to other classes of targeted therapies, cutaneous adverse effects are among the most frequent toxicities observed with mitogen-activated protein kinase pathway inhibitors, PI3K-AKTmTOR inhibitors, hedgehog signaling pathway inhibitors, and immunotherapies. Given the rapid expansion of these families of targeted treatments, dermatologists will be essential in offering dermatologic supportive care measures to cancer patients being treated with these agents. Part II of this continuing medical education article reviews skin-related adverse sequelae, including the frequency of occurrence and the implications associated with on- and off-target cutaneous toxicities of inhibitors of the RAS-RAF-MEKERK pathway, PI3K-AKT-mTOR pathway, hedgehog signaling pathway, and immunotherapies.

AB - The last decade has spawned an exciting new era of oncotherapy in dermatology, including the development of targeted therapies for metastatic melanoma and basal cell carcinoma. Along with skin cancer, deregulation of the PI3K-AKT-mTOR and RAS-RAF-MEK-ERK intracellular signaling pathways contributes to tumorigenesis of a multitude of other cancers, and inhibitors of these pathways are being actively studied. Similar to other classes of targeted therapies, cutaneous adverse effects are among the most frequent toxicities observed with mitogen-activated protein kinase pathway inhibitors, PI3K-AKTmTOR inhibitors, hedgehog signaling pathway inhibitors, and immunotherapies. Given the rapid expansion of these families of targeted treatments, dermatologists will be essential in offering dermatologic supportive care measures to cancer patients being treated with these agents. Part II of this continuing medical education article reviews skin-related adverse sequelae, including the frequency of occurrence and the implications associated with on- and off-target cutaneous toxicities of inhibitors of the RAS-RAF-MEKERK pathway, PI3K-AKT-mTOR pathway, hedgehog signaling pathway, and immunotherapies.

KW - AKT inhibitor

KW - Autoimmune adverse effects

KW - Autoimmune dermopathies

KW - B-RAF

KW - Dabrafenib

KW - Dermatitis

KW - Dual inhibitor

KW - Dysgeusia

KW - Everolimus

KW - Hair loss

KW - Hedgehog signaling pathway

KW - Immune-related toxicities

KW - Immunotherapy

KW - Ipilimumab

KW - Keratoacanthoma

KW - Keratosis pilaris

KW - Keratotic squamoproliferative lesion

KW - Lambrolizumab

KW - Loss of taste

KW - MAP kinase pathway

KW - MEK inhibitors

KW - mTOR inhibitor

KW - Nivolumab

KW - Panniculitis

KW - PD-1 inhibitor

KW - PI3 kinase inhibitor

KW - PI3K-AKT-mTOR pathway

KW - Pruritus

KW - RAF inhibitors

KW - Rapamycin

KW - RAS

KW - Seborrheic dermatitis

KW - Selumetinib

KW - Squamous cell carcinoma

KW - Taste alteration

KW - Temsirolimus

KW - Trametinib

KW - Vemurafenib

KW - Verrucal keratosis

KW - Vismodegib

KW - Vitiligo

UR - http://www.scopus.com/inward/record.url?scp=84922569171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922569171&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2014.07.033

DO - 10.1016/j.jaad.2014.07.033

M3 - Article

C2 - 25592339

AN - SCOPUS:84922569171

VL - 72

SP - 221

EP - 236

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -